DEF: Scilex Seeks Stockholder Approval for Option Repricing

Scilex Holding Company will hold a special meeting on December 11, 2025, to seek stockholder approval for repricing certain underwater stock options and for a potential meeting adjournment.

Summary

• Scilex Holding Company is convening a Special Meeting of Stockholders on December 11, 2025, to vote on two proposals.
• The primary proposal is to approve the repricing of certain stock options issued under the 2022 Equity Incentive Plan, held by eligible service providers.
• These options have exercise prices significantly above the current stock price, with some being more than 22 times the closing price of $12.78 per share on October 17, 2025.
• The Board believes repricing is necessary to restore incentive and retention value for employees and directors, avoiding the need for new equity grants or increased cash compensation.
• Approximately 289,405 options, representing 19% of all outstanding options, are eligible for repricing.
• Executive officers and non-employee directors hold approximately 94% of these eligible options.
• The new exercise price will be the fair market value (closing price on Nasdaq) on the Repricing Date.
• The second proposal seeks approval to adjourn the Special Meeting if insufficient votes are received for the Option Repricing Proposal.
• The Board of Directors unanimously recommends a "FOR" vote on both proposals.

Sentiment

Score: 3

Explanation: The filing reveals a significant decline in the company's stock price over the past three years, rendering most stock options "underwater" and ineffective as incentives. While the proposed option repricing aims to re-incentivize key talent and avoid further dilution or cash outlays, it is a direct consequence of poor past stock performance. The substantial compensation awarded to executives in 2023, particularly the large stock awards, contrasts sharply with the subsequent need for option repricing due to value erosion.

Positives

• The option repricing aims to re-incentivize and retain key talent, which is crucial for long-term stockholder value creation.
• Repricing avoids the immediate need to grant additional equity awards, which would further increase share overhang and dilution.
• It also avoids increasing cash compensation, which would reduce cash flow from operations.
• The virtual meeting format lowers costs and aligns with broader sustainability goals.

Negatives

• The company has experienced a "significant decline" in its stock price over the past three years, leading to most outstanding stock options being "significantly underwater."
• The exercise price of eligible options ($282.80 per share) is more than 22 times the recent closing price of $12.78 per share as of October 17, 2025, indicating substantial value erosion for existing option holders.
• The repricing could lead to incremental compensation cost under FASB ASC Topic 718.
• The repricing of Incentive Stock Options (ISOs) may cause them to lose their ISO qualification, potentially altering tax treatment for participants.

Risks

• Failure to approve the Option Repricing Proposal could lead to continued low morale and reduced retention among eligible service providers due to "underwater" options.
• Without repricing, the company might need to grant additional equity awards, increasing overhang, diluting stockholder interests, and raising non-cash operating expenses.
• Alternatively, increasing cash compensation as a retention tool would increase cash compensation expenses and reduce cash flow from operations, potentially adversely affecting business and results.
• Tax consequences related to the repricing of Incentive Stock Options (ISOs) could result in some options no longer qualifying as ISOs, leading to different tax treatment for participants.
• The company's stock price remains at a "significantly low level" compared to its previous price levels, indicating ongoing market challenges.

Future Outlook

The company's future outlook is implicitly tied to the success of the option repricing in motivating and retaining key talent. The Board believes the repricing will help build stockholder value and avoid further dilution or increased cash expenses. The company aims to continue linking pay to performance through equity compensation.

Management Comments

• "The purpose of the equity incentive plans and the equity awards granted thereunder is to provide an incentive for our employees and directors to focus on driving growth in our stock price and long-term stockholder value creation, and help us to attract and retain key talent in a competitive market."
• "Over the past three years, we have experienced a significant decline in our stock price and our stock price remains at a significantly low level compared to its previous price levels."
• "Most of the stock options currently outstanding have exercise prices that are above the recent trading prices of our Common Stock and certain stock options granted under the 2022 Plan that are currently outstanding have exercise prices that are significantly above (and in certain cases, more than 22 times) the recent trading prices of our Common Stock."
• "The Eligible Options... may be perceived by their holders as having little or no incentive and retention effect due to the difference between the exercise prices and the current stock price."
• "The Board believes that the Option Repricing is in the best interests of our stockholders and the Company and enables us to: assure that the existing equity awards that are significantly underwater provide meaningful compensatory opportunity to the Eligible Participants; motivate and engage the Eligible Participants to continue to build stockholder value; provide an increased level of retention of our Eligible Participants; and avoid the need to grant additional, incremental equity awards or provide increased cash compensation."

Industry Context

The filing highlights the competitive market for attracting and retaining key talent, suggesting that Scilex operates in an industry where equity incentives are a standard and critical component of compensation. The need for option repricing due to a significant stock price decline indicates that the company may be facing specific challenges or that its stock performance has lagged broader market or industry trends, making existing equity awards ineffective as incentives. The mention of avoiding increased cash compensation or further dilution suggests a focus on managing expenses and capital structure in a challenging environment.

Comparison to Industry Standards

• The company's compensation programs are designed to attract, retain, incentivize, and reward talented executives, aligning with common industry practices for competitive markets.
• The use of equity compensation, specifically stock options, is a key industry standard for linking pay to performance and aligning employee interests with stockholder value creation.
• The need for option repricing due to "underwater" options is a common issue faced by companies whose stock prices have significantly declined, and repricing is a recognized, though sometimes controversial, mechanism to restore incentive value, often seen in volatile or high-growth sectors where stock performance can be unpredictable.
• The consideration and rejection of an option exchange due to "tender offer rules" and "added costs, complexities and burdens on our already strained resources" suggests the company is navigating complex regulatory and financial constraints, which is typical for publicly traded companies, especially those facing financial pressures.

Management Changes

Corporate Governance

Related Party Transactions

• Inform LLC, a company affiliated with former CEO Jaisim Shah, entered into a consulting agreement with Scilex for a monthly fee of $50,000 for five years, effective September 22, 2025, following Mr. Shah's resignation.
• SCLX Stock Acquisition JV LLC, an indirect wholly owned subsidiary, holds 19.37% of Common Stock and 100% of Series A Preferred Stock. Its voting and dispositive power is controlled by an independent manager, Xiao Xu, until the Oramed Note and any Additional Notes are paid in full.
• Oramed Pharmaceuticals Inc. holds warrants to purchase 764,277 shares of Common Stock, exercisable within 60 days of October 17, 2025, with an exercise price of $0.01 per share, subject to a 9.99% beneficial ownership limitation.

Stakeholder Impact

• **Shareholders**: Potential benefit from re-incentivized management driving future stock price growth; voting on significant compensation matters; potential for future dilution if new options were granted instead of repricing.
• **Employees (Eligible Service Providers)**: Direct benefit from repriced options, restoring incentive value and improving retention; potential tax implications for Incentive Stock Options.
• **Management/Directors**: Direct benefit from repriced options, restoring incentive value; continued alignment with stockholder interests.
• **Creditors**: No direct impact mentioned, but the underlying stock price decline and efforts to retain talent could indirectly affect the company's long-term financial health and ability to meet obligations.

Next Steps

• Stockholders to vote on the Option Repricing Proposal and the Adjournment Proposal at the Special Meeting on December 11, 2025.
• If approved, eligible options will be repriced to the fair market value on December 11, 2025.
• The company will disclose voting results on a Current Report on Form 8-K within four business days after the Special Meeting.
• The 2022 Plan and ESPP will continue to have automatic annual share increases until January 1, 2032.

Key Dates

Recommendation

The company is addressing a critical issue of "underwater" stock options that have lost their incentive value due to a "significant decline" in stock price over the past three years. The proposed repricing is a necessary step to re-motivate and retain key talent, which is vital for future performance. However, the need for such a drastic measure highlights past poor stock performance. While the repricing aims to stabilize and re-energize the team, the underlying challenges that led to the stock price decline remain a concern. The substantial executive compensation in 2023, particularly the large stock awards, followed by the need for repricing, could raise questions about compensation effectiveness and governance. Investors should hold to observe if the repricing successfully re-aligns management incentives and translates into improved operational and stock performance, while carefully monitoring the company's ability to reverse its stock price trajectory.

Keywords

Scilex Holding Company, SCLX, Stock Options, Option Repricing, Equity Incentive Plan, Executive Compensation, Corporate Governance, Special Meeting, Proxy Statement, Shareholder Vote, Nasdaq, Underwater Options, Employee Retention, Stock Price Decline